# Jeffrey McPheeters

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jeffrey-mcpheeters/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,129 |
| Field | Hepatitis C virus research |
| h-index | 8 |
| i10-index | 6 |
| Last Known Institution | Optum (United States) |
| OpenAlex ID | https://openalex.org/A5065866173 |
| Works | 40 |

## Researcher papers

- [Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder](https://scholariq.org/papers/comparative-effectiveness-of-different-treatment-pathways-for-opioid-use/)
- [Persistence and Compliance Among U.S. Patients Receiving Pazopanib or Sunitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: A Retrospective Claims Analysis](https://scholariq.org/papers/persistence-and-compliance-among-u-s-patients-receiving-pazopanib-or-sunitinib/)
- [Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder](https://scholariq.org/papers/relative-cost-differences-of-initial-treatment-strategies-for-newly-diagnosed/)
- [Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States](https://scholariq.org/papers/treatment-discontinuation-adherence-and-real-world-effectiveness-among-patients/)
- [Factors Associated With Initial Treatment Choice, Engagement, and Discontinuation for Patients With Opioid Use Disorder](https://scholariq.org/papers/factors-associated-with-initial-treatment-choice-engagement-and-discontinuation/)
- [Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens](https://scholariq.org/papers/disease-burden-early-discontinuation-and-healthcare-costs-in-hepatitis-c/)
- [Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy](https://scholariq.org/papers/healthcare-utilization-and-costs-among-patients-with-herpes-zoster-and-solid/)
- [Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy](https://scholariq.org/papers/real-world-outcomes-in-patients-with-chronic-obstructive-pulmonary-disease/)
- [Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin](https://scholariq.org/papers/comparison-of-healthcare-resource-utilization-and-costs-in-patients-with-type-2/)
- [Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes](https://scholariq.org/papers/diagnostic-testing-managed-by-hematopathology-specialty-and-other-laboratories/)
- [0808 Describing the Healthcare Providers of Patients with Narcolepsy or Idiopathic Hypersomnia in US Clinical Practice](https://scholariq.org/papers/0808-describing-the-healthcare-providers-of-patients-with-narcolepsy-or/)

## Researcher topics

- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [Herpesvirus Infections and Treatments](https://scholariq.org/topics/herpesvirus-infections-and-treatments/)
- [Cytomegalovirus and herpesvirus research](https://scholariq.org/topics/cytomegalovirus-and-herpesvirus-research/)
- [Substance Abuse Treatment and Outcomes](https://scholariq.org/topics/substance-abuse-treatment-and-outcomes/)

## Researcher university

- [Optum (United States)](https://scholariq.org/institutions/optum-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.